U.S. Markets open in 2 hrs 53 mins

Wired News – Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300

Stock Monitor: Sinovac Biotech Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ONTX. On December 19, 2017, the Phase-3-stage biopharmaceutical Company, working towards discovering and developing small molecule drug candidates to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), declared that it has entered into a license and collaboration agreement with the oncology specialty Company HanX Biopharmaceuticals Inc. ("HanX") for the further development, registration, and commercialization of ON 123300 in China. The market reacted positively to this development as Onconova shares were up 16% pre-market on light volume. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Sinovac Biotech Ltd (NASDAQ: SVA), which also belongs to the Healthcare sector as the Company Onconova Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SVA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Onconova Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ONTX

About ON 123300

ON 123300 is a first-in-class dual inhibitor of CDK4/6 and ARK5, which is currently in advanced pre-clinical development. It is believed that ON 123300 has the potential to overcome the limitations of current generation CDK 4/6 inhibitors.

The main challenge with cancer cells is that they multiply rapidly. CDK inhibitors disrupt this process by blocking the activity of CDK enzymes. CDK4 and CDK6 regulate cell cycle progression at the G1 restriction point, and are hence considered potential anticancer drug targets.

Onconova showcased pre-clinical data on in-vitro metabolism and bioavailability of ON 123300 at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in November 2017. The data revealed the improved understanding of the metabolism of ON 123300 and the identification of metabolites. It also showed two- to three-fold increase in bioavailability due to the Company's formulation development efforts.

Terms and Conditions of the Agreement

  • As per the agreement, HanX will commercialize ON 123300 in Greater China while Onconova would retain the rights for the rest of the world.
  • The agreement states HanX will provide all funding required for Chinese IND enabling studies performed for the Chinese Food and Drug Administration IND approval. Besides, both Companies expect these studies to comply with the US Food and Drug Administration (FDA) standards. Afterwards, Onconova could possibly use these studies for an IND filing with the FDA. Both Onconova and HanX will oversee the IND enabling studies.
  • In terms of compensation, Onconova will receive an upfront payment, regulatory and commercial milestone payments, as well as royalties on Chinese sales.

Collaboration to Accelerate Advancement of ON 12330

This agreement aims to advance ON 123300 towards a US IND as Onconova aims to create a new standard of care to overcome the limitations of current generation compounds that depend on a combination treatment for therapy. On the other hand, ON 123300 has the potential to act as a single agent, due to the unique targeting of ARK5, as well as CDK4 and 6, making it potentially suitable for indications that may not be responsive to the current generation of CDK4/6 inhibitors, such as Palbociclib.

Onconova intends to focus on its later stage rigosertib clinical development programs in MDS, and looks forward to leveraging the strong expertise of HanX in drug development and commercialization.

HanX Expects to Gain from Potential Synergies

HanX has an emerging pipeline of targeted agents such as proprietary PD-1 checkpoint antibody, which is expected to enter its Phase-1 trial soon. Onconova and HanX share a similar commitment towards developing innovative therapeutics in oncology. Both Companies are collaborating for the development of ON 123300 for patients suffering from many types of cancer, including breast cancer, in China and globally. HanX looks forward to the potential synergies between its pipeline of checkpoint product candidates and Onconova's CDK inhibitors.

Stock Performance Snapshot

December 20, 2017 - At Wednesday's closing bell, Onconova Therapeutics' stock advanced 2.74%, ending the trading session at $1.50.

Volume traded for the day: 103.65 thousand shares.

After yesterday's close, Onconova Therapeutics' market cap was at $16.31 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors